Adderall XR Sales Rebounding, Shire Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of Shire's attention deficit/hyperactivity disorder agent Adderall XR (extended-release amphetamine) are rebounding after negative publicity that followed Health Canada's suspension of the product